Focetria, a new human vaccine from Novartis (Basel, Switzerland, www.novartis.com) designed for use following the declaration of an influenza pandemic, has received European Union (EU) approval in all 27 member states as well as Iceland and Norway.
Focetria, a new human vaccine from Novartis (Basel, Switzerland, www.novartis.com) designed for use following the declaration of an influenza pandemic, has received European Union (EU) approval in all 27 member states as well as Iceland and Norway. Focetria will be manufactured to contain the influenza strain declared at the time of a pandemic by the World Health Organization (WHO). It will also include the proprietary adjuvant MF59, developed by Novartis, which could extend the vaccine supply by allowing for smaller amounts of viral antigens to be used in each dose compared to vaccines without this adjuvant.
Novartis has also received a positive opinion supporting EU approval of its cell culture–derived seasonal influenza vaccine Optaflu, which is aiming to become the first influenza vaccine to utilize a mammalian cell line, rather than chicken eggs, for antigen production. The Committee for Medicinal Products for Human Use (CHMP), which reviews applications for all 27 countries in the EU as well as Iceland and Norway, has recommended approval of this new vaccine. The EU generally follows the recommendations of the CHMP and delivers its final decision within two to three months.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.